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Background: Pro-inflammatory/cytotoxic T cells (IFNγ, TNFα, granzyme B+) are increased in the peripheral
circulation in COPD. NKT-like and NK cells are effector lymphocytes that we have also shown to be major sources of
pro-inflammatory cytokines and granzymes. P-glycoprotein 1 (Pgp1) is a transmembrane efflux pump well
characterised in drug resistant cancer cells. We hypothesized that Pgp1 would be increased in peripheral blood T,
NKT-like and NK cells in patients with COPD, and that this would be accompanied by increased expression of IFNγ,
TNFα and granzyme B. We further hypothesized that treatment with cyclosporine A, a Pgp1 inhibitor, would render
cells more sensitive to treatment with corticosteroids.
Methods: Pgp1, granzyme B, IFNγ and TNFα expression were measured in peripheral blood T, NK and NKT-like cells
from COPD patients and control subjects (± cyclosporine A and prednisolone) following in vitro stimulation and
results correlated with uptake of efflux dye Calcein-AM using flow cytometry.
Results: There was increased Pgp1 expression by peripheral blood T, NKT-like and NK cells co-expressing IFNγ,
TNFα and granzyme B in COPD patients compared with controls (e.g. %IFNγ/Pgp1 T, NKT-like, NK for COPD
(Control): 25(6), 54(27), 39(23)). There was an inverse correlation between Pgp1 expression and Calcein-AM uptake.
Treatment with 2.5 ng/ml cylosporin A and10-6 M prednisolone resulted in synergistic inhibition of pro-
inflammatory cytokines in Pgp1 + cells (p < 0.05 for all).
Conclusions: Treatment strategies that target Pgp1 in T, NKT-like and NK cells may reduce systemic inflammatory
mediators in COPD and improve patient morbidity.
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COPD is predicted to be the 3rd leading cause of death
worldwide by 2020 [1]. Existing treatments are largely
symptomatic and the only approved anti-inflammatory
medication, corticosteroids, has no proven disease modi-
fying effect [1]. Inhaled corticosteroids have major bene-
fits for the treatment of airway inflammation in asthma,
but the reason for their relative lack of efficacy in COPD
is both poorly understood and a major limiting factor in
COPD treatment. Thus, better understanding of the
mechanisms underlying steroid resistance in COPD, and* Correspondence: greg.hodge@health.sa.gov.au
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reproduction in any medium, provided the ora way to circumvent this to take better advantage of
existing therapies would have an immediate clinical
impact.
COPD is a systemic disease and may represent a
“spill-over” of inflammatory events occurring in the
lungs [2]. In this regard we have previously shown an in-
crease in pro-inflammatory/cytotoxic T cells, NKT-like
and NK cells in the peripheral blood and airways in
COPD patients compared with non-COPD smokers
where some changes were only noted in the lungs com-
pared with healthy controls [3-5].
P-glycoprotein 1 (Pgp1) is a transmembrane efflux
pump well characterised in drug resistant cancer cells
[6]. We hypothesized that Pgp1 may play a role in ster-
oid resistance and would be increased in peripheralLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and that this would be accompanied by increased ex-
pression of IFNγ, TNFα and granzyme B. We further hy-
pothesized that treatment with low dose cyclosporine A,
a Pgp1 inhibitor, would render cells more sensitive to
treatment with corticosteroids.
Pgp1, granzyme B, IFNγ and TNFα expression were
measured in peripheral blood T, NK and NKT-like cells
from COPD patients and control subjects (± cyclospo-
rine A and prednisolone) following in vitro stimulation
and results correlated with uptake of efflux dye calcein
AM using flow cytometry.
Methods
Patient and control groups
COPD patients and controls were recruited for the study
and fully informed consent obtained. There was no ex-
acerbation of COPD for 6 weeks prior to involvement in
the study. Ethics approval was obtained from the Royal
Adelaide Hospital. The diagnosis of moderate COPD
was established using the GOLD criteria [7] of a relevant
history and post bronchodilator FEV1 30-80% of pre-
dicted and FEV1/FVC < 70%.
Blood was collected from 10 patients with COPD
(Table 1) of whom all were ex-smokers (at least one year).
Blood was also obtained from 14 non-smoking volun-
teers (Table 1) with no history of airways disease and
normal lung function).
Leucocyte counts
Full blood counts, including white cell differential counts,
were determined on blood specimens using a CELL-DYN
4000 (Abbot Diagnostics, Sydney, Australia). Blood films
were stained by the May-Grunwald-Giemsa method and
white cell differential counts checked by morphological
assessment microscopically.
CD3, CD4 and CD8 cell counts
The percentages of CD3, CD4 and CD8 lymphocytes were
calculated using flow cytometry. One hundred microlitre
of peripheral blood were stained with appropriatelyTable 1 Demographic details of the COPD and control
subjects
Subjects Controls COPD
No. of subjects 14 10
Age (years) 56 (± 8) 58 (± 16)
FEV1, % pred 110.4 (± 9) 60.5 (± 20)
FEV1, % FVC 96 (± 12) 58 (± 15)*
Male/Female 8/6 6/4
Data shown as mean ± SEM.
Abbreviations: COPD: chronic obstructive pulmonary disease. FEV1: forced
expiratory volume in 1 second; FVC: forced vital capacity; *P < 0.05 compared
to controls.diluted fluorescently conjugated monoclonal antibodies as
previously described [3].
Granzyme B expression by T, NKT-like and NK cells
The percentages of T, NKT-like and NK cells expressing
granzyme B, was determined as previously reported [5].
Leucocyte stimulation
Leucocyte stimulation was required for both intracellular
cytokine and Pgp1 expression by T, NKT-like and NK
cells. One mL aliquots of blood (diluted 1:2 with RPMI
1640 medium) were placed in a 10 mL sterile conical PVC
tubes (Johns Professional Products, Sydney, Australia).
Phorbol myristate (25 ng/mL) (Sigma, Sydney, Australia)
and ionomycin (1 μg/mL) (Sigma) was added. Brefeldin A
(10 μg/mL) was added as a “Golgi block” (Sigma) and the
tubes re-incubated in a humidified 5% CO2/95% air at-
mosphere at 37°C for 16 h.
Intracellular IFNγ and TNFα expression by T, NKT-like and
NK cells
Three hundred and fifty μL of stimulated peripheral
blood cells were stained with appropriately diluted fluo-
rescently conjugated monoclonal antibodies as previ-
ously reported [3-5] to IFNγ FITC (BD Biosciences,
Sydney, Australia) (BD), CD3 perCP.Cy5.5 (BD), CD56
APC (Beckman Coulter, Sydney, Australia), TNFα V450,
granzyme B V450 and CD45 V500 (BD). Samples were
analysed by gating using forward scatter (FSC) versus
side scatter (SSC) to exclude platelets and debris. Gated
cells were analysed with CD45 V500 (BD) to ascertain that
cells were of lymphoid origin. A minimum of 500,000
CD45 positive, low SSC events were acquired on a
FACSCanto II (BD) in list-mode format for analysis using
FACSDiva software (BD). T cells were identified as events
that were CD3 + CD56-, NK cells as CD3-CD56+ and
NKT-like cells as CD3 +CD56+ events as previously
reported [5].
Pgp1 expression by T, NK and NKT-like cells
Preliminary experiments showed that cells required stimu-
lation for significant Pgp1 molecule expression by T,
NKT-like and NK cells. Following stimulation as described
above, 350 μL aliquots of cells were treated with 2 mL
FACSLyse for 10 min. Cells were centrifuged, supernatant
discarded and 500 mL FACSPerm added for 10 min. Two
mL 0 · 5% bovine serum albumin (BSA) (Sigma) in IsoFlow
(Beckman Coulter) was then added and the tubes
centrifuged at 300 g for 5 min. After decanting super-
natant, Fc receptors were blocked with 10 mL human im-
munoglobulin (Intragam, CSL, Melbourne, Australia) for
10 min at room temperature. Five μL of appropriately di-
luted CD3 perCP.Cy5.5 (BD), Pgp1 PE (BD) CD56 APC
(Beckman Coulter) and CD45 V500 (BD) or isotype
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temperature. Cells were washed and events acquired and
analyzed as described above.Pgp1, IFNγ, TNFα and granzyme B expression by T,
NKT-like and NK cells
To determine possible association of pro-inflammatory
cytokines and granzyme B expression with Pgp1 expres-
sion by T, NKT-like and NK cells, whole blood was stim-
ulated as described above. Following stimulation and
processing, 5 μL of appropriately diluted IFNγ FITC
(BD), granzyme B FITC (BD), Pgp1 PE (BD), CD3
perCP.Cy5.5 (BD), TNFα V450 (BD) and CD45 V500
(BD) were added for 15 min in the dark at room
temperature. Cells were washed and events acquired and
analyzed as described above.Uptake of Calcein-AM by T, NKT-like and NK cells
To determine functional Pgp1 activity, efflux of Calcein-
AM was analysed in T, NKT-like and NK cells as previ-
ously published [8] from a cohort of COPD patients and
control subjects. Briefly, following stimulation of cells as
described above, 5 nM Calcein-AM (eBioscience, San
Diego, CA, USA) was added and cells re-incubated in a
humidified 5% CO2/95% air atmosphere at 37°C for
30 min. Aliquots were washed twice with wash buffer to
remove free Calcein-AM and cells processed for Pgp1
expression as described above.Effect of methylprednisolone and Cyclosporin A on Pgp1,
IFNγ, TNFα and granzyme B expression by T, NKT-like and
NK cells
To determine the effects of methylprednisolone and
Cyclosporin A on Pgp1, IFNγ, TNFα and granzyme B ex-
pression by T, NKT-like and NK cell subsets, one mL al-
iquots of blood (diluted 1:2 with RPMI 1640 medium)
were placed in a 10 mL sterile conical PVC tubes with
10-6 M methylprednisolone and/or various concentra-
tions of Cyclosporin A (0, 1, 2.5, 5, 10, 50, 100, 200 and
250 ng/mL) for 24 h in a humidified 5% CO2/95% air at-
mosphere at 37°C. Blood cultures were then stimulated
as described above for 16 h and processed for Pgp1,
IFNγ, TNFα, granzyme B and perforin expression by T,
NKT-like and NK subsets as described above.Figure 1 Pgp1 + T, NKT-like and NK cells in COPD and control
subjects. Data presented as box plots. There was a significant
increase in the percentage of Pgp1 + NKT-like and Pgp1 + NKcells in
COPD patients (grey bars) compared with control subjects (clear
bars). The percentage of Pgp1 + NKT-like and Pgp1 + NK cells was
greater than the percentage of Pgp1 + T cells for COPD patients but
not control subjects (p > 0.05 for all).Statistical analysis
Statistical analysis was performed using Mann–Whitney
and Spearman Rho correlation tests using SPSS software
and differences between groups of P < 0.05 considered
significant.Results
Blood CD4+ and CD8+ T cell counts
There was a significant increase in the absolute number
of CD8 T cells in blood from COPD patients compared
with controls (0.43 ± 0.22 and 0.33 ± 0.16 × 109/L for
COPD patients and controls respectively, P = 0.047).
There were no other significant differences in the abso-
lute counts of CD3+, CD4+ or CD8+ absolute counts.
The percentage of CD8+ T cells was significantly in-
creased and CD4+ T cells significantly decreased in the
COPD group compared to the control group (57 ± 8
and 69 ± 7 for CD4 and 43 ± 9 and 31 ± 8 for CD8 for
COPD patients and controls respectively, P = 0.032 and
P = 0.037 respectively). The percentage of CD4-CD8-
and CD4 + CD8+ T cells was < 3% for all patient and
control subjects. There was no change in the percentage
or absolute numbers of NK and NKT-like cells between
COPD patients and control group (p < 0.05 for all) con-
sistent with our previous report [9] (data not shown).Pgp1 expression by T, NKT-like and NK cells
There was no significant differences in Pgp1 expression
by stimulated CD3+ T cells (Figure 1). There was how-
ever a significant increase in Pgp1 expression by NKT-
like and NK cells from COPD patients versus controls
(Figure 1). Pgp1 expression was higher in NKT-like and
NK cells than T cells for COPD patients but not control
subjects (p > 0.05 for all).
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NK cells
There was no significant increase in IFNγ expression by
stimulated CD3+ T cells from COPD patients versus
controls (Figure 2a). There was however a significant in-
crease in IFNγ expression by NKT-like and NK cells in
COPD patients compared with controls (Figure 2a).
There was a significant increase in both TNFα and
granzyme B expression by CD3+ T, NKT-like and NK
cells in COPD patients compared with controls (Figure 2b
and 2c).IFNγ, TNFα and granzyme B expression by Pgp1+ T, NKT-
like and NK cells
There was a significant increase in IFNγ, TNFα and
granzyme B expression by Pgp1+ T, NKT-like and NK
cells in COPD patients compared with controls (Figure 3a,
3b and 3c). Granzyme B expression was significantly in-
creased in stimulated T, NKT-like and NK cells from
both COPD patients and controls compared with non-
stimulated blood (p < 0.05 for all) (data not shown).
Representative dot plots showing increased IFNγ ex-
pression by Pgp1+ T, NKT-like and NK cells from a pa-
tient with COPD compared with a control subject are
shown in Figure 4.Correlation between Pgp-1 expression and Calcein-AM
expression by T, NKT-like and NK cells
Calcein-AM has been shown to enter cells that are defi-
cient in Pgp1 expression [8]. There was a significant nega-
tive correlation between Pgp1 expression and Calcein-
AM uptake by T (R = .893, p = .012) (Figure 5), NKT-
like (R = .901, p = .008) and NK cells (R = .915, p = .004)
from a cohort of 6 COPD patients and 6 control
subjects.Figure 2 IFNγ +, TNFα and Granzyme b + T, NKT-like and NK cells in C
was a significant increase in IFNγ expression by NKT-like and NK cells in CO
T cells. b. There was a significant increase in TNFα expression by T, NKT-like
significant increase in granzyme b expression by T, NKT-like and NK cells inEffect of methylprednisolone and Cyclosporin A on Pgp1,
IFNγ, TNFα and granzyme B expression by T, NKT-like and
NK cells
The inhibitory effect of 10-6 M methylprednisolone
alone and in combination with 2.5 ng/mL Cyclosporin A
on Pgp1, IFNγ, TNFα and granzyme B expression by T,
NKT-like and NK cells are shown in Table 2. The inhibi-
tory effect of 10-6 M methylprednisolone on IFNγ and
TNFα expression by NK cells was greater than for T and
NKT-like cells. In the presence of 2.5 ng/mL Cyclosporin
A there was a significant inhibition of IFNγ and TNFα ex-
pression by all subsets. The combination of 10-6 M meth-
ylprednisolone and 2.5 ng/mL Cyclosporin A resulted in a
synergistic inhibition of IFNγ and TNFα expression by T
and NKT-like cells. Representative plots showing the com-
bined inhibitory effect of 10-6 M methylprednisolone and
2.5 ng/mL Cyclosporin A on IFNγ expression by Pgp1+ T
and NKT-like cells are shown in Figure 6. Higher concen-
trations of Cyclosporin A (>10 ng/mL) resulted in almost
complete inhibition of IFNγ and TNFα expression by T,
NKT-like and NK cells (data not shown). There was no in-
hibitory effect of 10-6 M methylprednisolone on granzyme
B expression by T, NKT-like and NK cells. Significant in-
hibition of granzyme B expression by T, NKT-like and NK
cells was only noted in the presence of 200 ng/mL and
250 ng/mL Cyclosporin A (e.g., 10 ± 4, 1 ± 2, 4 ± 3% in-
hibition of granzyme B in the presence of 200 ng/ml
Cyclosporin A and 28 ± 8, 6 ± 4, 18 ± 6% inhibition of
granzyme B in the presence of 250 ng/mL Cyclosporin
A by T, NKT-like and NK cells respectively). The
addition of 10-6 M methylprednisolone resulted in no
additional effect on Pgp1 expression by any cell subset
(data not shown). To determine the association of Pgp1
expression with drug resistance, the inhibitory effect of
the various drug combinations on IFNγ and TNFα
expression by Pgp1+ T, NKT-like and NK cells wasOPD and control subjects. Data presented as box plots. a. There
PD patients (grey bars) compared with controls (clear bars) but not
and NK cells in COPD patients compared with controls. c. There was a
COPD patients compared with controls.
Figure 3 Pgp1+ T, NKT-like and NK cells producing IFNγ, TNFα and Granzyme b in COPD and control subjects. Data presented as box
plots. a. There was a significant increase in IFNγ expression by Pgp1+ T, NKT-like and NK cells in COPD patients compared with controls. b. There
was a significant increase in TNFα expression by Pgp1+ T, NKT-like and NK cells in COPD patients compared with controls. c. There was a
significant increase in granzyme b expression by Pgp1+ T, NKT-like and NK cells in COPD patients compared with controls.
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for total IFNγ and TNFα expression by Pgp1+ T, NKT-
like and NK cells (Table 3) and suggests a strong associ-
ation between Ppg1 expression and drug resistance in T,
NKT-like and NK cells.Figure 4 Representative dot plots showing increased IFNγ expression
(bottom row) compared with a control subject (upper row).Discussion
This is the first study to show differential expression of
the drug efflux pump Pgp1 by T, NKT-like and NK cells
from COPD patients compared with healthy control
subjects. COPD is a systemic disease [2] and we haveby Pgp1+ T, NKT-like and NK cells from a patient with COPD
Figure 5 Correlation between Calcein-AM and Pgp1 in T cells.
Graph of Calcein-AM + CD3+ versus Pgp1 + CD3+ T cells. There was
a significant negative correlation between Pgp1 expression and
Calcein-AM uptake by CD3 + T cells from a cohort of 6 COPD
patients and 6 control subjects.
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[3], granzyme B by NK and NKT-like cells [5] and
granzyme B by T cells [4] in the peripheral blood and
lungs of COPD patients. Our novel findings that Pgp1 is
up-regulated in NKT-like and NK cells in patients with
COPD and that this is associated with increased pro-
inflammatory and cytotoxic molecules in T, NKT-like
and NK cells have important implications for treatment
strategies to target these cells.
The relative lack of corticosteroid efficacy in COPD
has been poorly understood and a major limiting factor
in COPD treatment [2]. We now show that production
of IFNγ and TNFα and granzyme B by T and NKT-like
subsets of lymphocytes are not inhibited with thera-
peutic doses of methylprednisolone, a commonly used
corticosteroid in vitro, confirming clinical findings. Im-
portantly we show that by targeting Pgp1 with a low
dose of the inhibitor, cyclosporine A, production of the
pro-inflammatory cytokines IFNγ and TNFα are signifi-
cantly inhibited. Further, a combination of very low dose
cyclosporine A (2.5 ng/mL) with standard dose methyl-
prednisolone (10-6 M), results in synergistic inhibition ofTable 2 The inhibitory effect of 10-6 M methylprednisolone (M
A (CsA) on IFNγ and TNFα expression by T, NKT-like and NK c
IFNγ
Drug Dose of drug T NKT
MP 10-6 M 2 ± 2* 5 ± 3
CsA 2.5 ng/ml 47 ± 9 44 ±
MP + CsA 10-6 M + 2.5 ng/ml 88 ± 7 83 ±
The combination of 10-6 M methylprednisolone and 2.5 ng/mL Cyclosporin A result
NKT-like cells.
* The percentage inhibition of IFNγ and TNFα by T, NKT-like and NK cells comparedthese pro-inflammatory cytokines known to have sys-
temic effects in patients with COPD [2]. The excellent
negative correlation between efflux of Calcein-AM, pre-
viously shown to identify Pgp1 function in cells [8] and
our findings of Pgp1 expression in T, NKT-like and NK
cells confirms these novel findings.
Our group has undertaken pioneering work on the role
of T-cell pro-inflammatory cytokines, particularly TNFα
and IFNγ, and their role in COPD [3]. T cells are a major
inflammatory cell type present in the lung in COPD pa-
tients. Our findings in 2007 were the first comprehensive
report of intracellular pro- and anti-inflammatory T cell cy-
tokines in the separate compartments of blood, bronchoal-
veolar lavage and intraepithelial T cells from bronchial
brushings from COPD subjects and smokers. Interestingly,
T-cell derived TNFα has been shown to cause apoptosis of
airway epithelial cells and impair the clearance of these
cells by alveolar macrophages [10]. Recently, TNFα has
been described as the “driving force behind COPD” [11],
and induction of TNFα in the lung has been shown to re-
sult in emphysema in the mouse model [9]. TNFα has also
been shown to induce IL-2Rs and IFNγ production by T
cells and activate neutrophils, macrophages, endothelial
cells and fibroblasts [12]; cells that play important roles in
the pathogenesis of COPD [2]. Recently it has been shown
that fractalkine, a potent chemoattractant for monocytes
and T cells produced by airway smooth muscle cells, was
induced in the presence of both IFNγ and TNFα [13]. Fur-
thermore, increased TNFα levels have been shown to be
increased in diseases associated with COPD such as car-
diovascular disease and as such, systemic treatment with
low dose Cyclosporin A and prednisolone may result in
improvements of a broad range of inflammatory conditions
associated with COPD [14].
An important extension of this work would be to
study T, NKT-like and NK cells in both the airways and
lung tissue of COPD patients as we have previously done
[5,15] to determine the role Pgp1 may play in steroid re-
sistance in these compartments. If this hypothesis is cor-
rect, targeting the airways with inhaled low dose CsA
combined with steroid may be the treatment of choice
to inhibit these pro-inflammatory molecules associated
with COPD disease.P) alone and in combination with 2.5 ng/mL Cyclosporin
ells are shown (mean ± SEM)
TNFα
NK T NKT NK
44 ± 8 2 ± 2 3 ± 2 47 ± 9
7 91 ± 5 51 ± 6 31 ± 9 92 ± 8
7 96 ± 6 81 ± 7 76 ± 7 96 ± 8
ed in the synergistic inhibition of IFNγ and TNFα expression by T and
with control (same specimen) without drug/s.
Figure 6 Representative plots showing the combined inhibitory effect of 10-6 M methylprednisolone and 2.5 ng/mL Cyclosporin A on
IFNγ expression by Pgp1+ T and NKT-like cells (lower plots) compared with media only (top plots).
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lymphocyte subsets in the peripheral blood of smokers
who have not progressed to COPD. Our previous findings
of increased T-cell production of IFNγ and TNFα in the
peripheral blood of COPD patients but not smokers with-
out COPD suggests Pgp1 may not be upregulated in
smokers who have not progressed to COPD. However,Table 3 The inhibitory effect of 10-6 M methylprednisolone (MP
(CsA) on IFNγ and TNFα expression by Pgp1+ T, NKT-like and N
IFNγ
Drug Dose T NKT
MP 10-6 M 2 ± 2* 4 ±
CsA 2.5 ng/ml 50 ± 10 46 ±
MP + CsA 10-6 M + 2.5 ng/ml 81 ± 5 76 ±
The combination of 10-6 M methylprednisolone and 2.5 ng/mL Cyclosporin A result
NKT-like cells.
* The percentage inhibition of IFNγ and TNFα by Pgp1+ T, NKT-like and NK cells cothere may be a subset of susceptible smokers who do have
increased Pgp1 in these cells who have an increased risk
of developing COPD and further studies are warranted to
investigate this hypothesis.
Our present findings show that there was a significant
increase in Pgp1 expression by T and NKT-like cells
compared with NK cells suggesting these subsets of) alone and in combination with 2.5 ng/mL Cyclosporin A
K cells are shown (mean ± SEM)
TNFα
NK T NKT NK
3 45 ± 9 3 ± 2 5 ± 2 49 ± 9
8 89 ± 7 54 ± 6 27 ± 6 87 ± 7
8 96 ± 7 78 ± 7 72 ± 8 97 ± 9
ed in the synergistic inhibition of IFNγ and TNFα expression by Pgp1+ T and
mpared with control (same specimen) without drug/s.
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therapeutic drugs.
We showed that the cytotoxic molecule, granzyme B is
unaltered by standard dose methylprednisolone and re-
quires much higher concentrations of cyclosporine usu-
ally used for immunosuppression in patients such as
those following lung transplantation [16]. Our results
suggest that patients with high levels of this cytotoxic
molecule may require treatment with higher dose Cyclo-
sporin A. Further, identification of patients with high
levels of granzyme B and response following treatment
may allow tailoring therapeutics to individual patients
using these techniques, to optimize immunosuppression
as to possibly avoid problems associated with over-
immunosuppression (e.g., infection and malignancy) and
under-immunosuppression with worsening of COPD
symptoms.
Conclusion
In conclusion, COPD is associated with increased Pgp1
expression by peripheral blood T, NKT-like and NK cells
co-expressing IFNγ, TNFα and granzyme B. Treatment
strategies that target Pgp1 in T, NKT-like and NK cells
may reduce systemic inflammatory mediators in COPD
and improve patient morbidity.
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